SCHEMBL24076861

SCHEMBL24076861

C=C(C)c1n[nH]c(=O)c2ccc(C(F)(F)F)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 1/20 0.44
▸ MAPT P10636 3/20 0.42
▸ MAP2K4 P45985 4/20 0.41
▸ MAPK1 P28482 3/20 0.41
▸ MAPK6 Q16659 3/20 0.41
▸ MAPKAPK3 Q16644 2/20 0.41
▸ MAPKAPK2 P49137 1/20 0.41
▸ AURKB Q96GD4 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ PARP1 P09874 1/20 0.40
▸ MAPKAPK5 Q8IW41 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ KIF11 P52732 1/20 0.39
▸ ROCK1 Q13464 3/20 0.39
▸ PRMT5 O14744 1/20 0.39
▸ WDR77 Q9BQA1 1/20 0.39
▸ GSK3B P49841 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24076276 0.89 MAPT (0.36) PDE2AMAPTAURKBMEN1USP2
SCHEMBL25746187 0.87 KMT2A (0.36) MAPK1MEN1KMT2APARP1SMN1; SMN2
SCHEMBL24077389 0.87 ATM (0.44) PDE2AMAPTMAP2K4MAPK1MAPK6
SCHEMBL24077092 0.82 POLB (0.47) PDE2AMAPTMEN1USP2KMT2A
SCHEMBL29874776 0.81 TSHR (0.39) MAPTMAP2K4MAPK1MAPK6KMT2A
SCHEMBL24076274 0.80 HTT (0.43) SMN1; SMN2ROCK1PRMT5WDR77GSK3B
SCHEMBL30168572 0.77 MEN1 (0.47) MAPTMAP2K4MAPK1MAPK6MAPKAPK3
SCHEMBL24076884 0.77 MEN1 (0.47) MAPTMAP2K4MAPK1MAPK6MAPKAPK3
SCHEMBL29874887 0.76 ROCK1 (0.48) MAPTHSD17B10ROCK1PRMT5WDR77
SCHEMBL29875213 0.75 TSHR (0.39) MAP2K4MAPK1MAPK6KMT2APARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
CN-115667225-A Compound (I) 詹森药业有限公司 2023-01-31 — — CN disclosed
WO-2021239885-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202989-A1 COMPOUNDS NLRP3, NLRP1, IL1B PDE2A 1750/4885MAPT 1004/4885MAP2K4 4395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback